Arecor Therapeutics plc
(“Arecor” or the “Group”)
ARECOR APPOINTS DR HELEN PARRIS AS SENIOR VICE PRESIDENT, COMMERCIAL AND GENERAL MANAGER OF TETRIS PHARMA LTD
Cambridge, UK, 3 January 2024: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today’s therapies to enable healthier lives, is pleased to announce the appointment of Dr. Helen Parris as Senior Vice President, Commercial and General Manager of the Group’s subsidiary company, Tetris Pharma Ltd ("Tetris Pharma”), effective Monday 15 January 2024.
Helen has over 20 years of scientific, commercial and…
James Sheppard, Managing Director (UK&I) at Kadans
Maintaining the pace of innovation required during the pandemic was never going to be easy. From the boom in demand in 2020, to the inflationary and market pressures in 2023, it has been a turbulent few years for the life sciences industry.
As companies continue to adapt to soaring energy bills, tighter budgets, and a new way of working, they are still expected to keep pace with innovation and deliver outstanding results for the industry. In turn, demand for specialised office and laboratory facilities is soaring to satisfy these needs,…
VANCOUVER, Wash., US and OXFORD, UK, December 20, 2023 — Absci (Nasdaq: ABSI), a generative AI drug creation company, and PrecisionLife®, a leading computational biology company driving precision medicine in complex chronic diseases, today announced a collaboration to develop a joint portfolio of potential therapeutics addressing unmet medical needs. The collaboration combines Absci’s speed and strength in antibody design and optimization with PrecisionLife’s deep understanding of complex disease biology and expertise in identifying the mechanisms, drug targets and treatments that are…
Financing led by Maven Capital Partners, alongside Gresham House Ventures
Funds to be used to expand Metrion’s Cambridge UK laboratories and to enhance scientific and commercial capabilities
Dr David Milroy and Steve Carle appointed to the board
Cambridge, UK, 20 December 2023: Metrion Biosciences Limited (Metrion), the specialist ion channel CRO and drug discovery company, today announced that it has secured £3.5m in new equity financing, including £2.5m from lead investor Maven Capital Partners (Maven) and £1 million from existing investor, Gresham House Ventures (Gresham…
New Scientist, in association with SRG, is conducting a global salary, employment and industry survey (Life Sciences, Clinical & Engineering) to provide you with the latest insights into your salary. The results of this survey benchmarking salary will be published on the SRG website. Be part of the conversation and participate today!The questionnaire takes 5 - 10 minutes to complete and, as a thank you, all respondents who complete the survey will be entered into a prize draw to win one of three £150 Amazon vouchers (or local equivalent). The information you provide will only be used…
AMSBIO has expanded its range of high-performance magnetic beads for use as detection labels in magnetic immunoassays or as a solid support phase in immunoassays.
MagSi-STA beads are magnetic silica particles with high quality streptavidin covalently attached to the bead surface. Available in different mean sizes, streptavidin coupling chemistries and binding capacities, these industry-leading MagSi-STA beads offer an optimized solution for many in vitro diagnostic applications, including immunoassays.
To streamline the process of selecting the most suitable streptavidin beads for…
London, 18th December 2023 - Kadans Science Partner (“Kadans”) has added a new asset in King’s Cross, London, UK to its Pan-European portfolio. The new asset at 22-23 Tileyard Road will be delivered as purpose built, high-quality laboratory accommodation, providing much needed technical real estate to the King’s Cross and London market. The asset was acquired from City & Provincial Properties. This latest acquisition continues to grow Kadans’ footprint in the Knowledge Quarter, London, a global centre of excellence for science & technology innovation.
The Knowledge Quarter Kings…
Read the December eNews #lifescience newsletter featuring:✅ Welcome from Tony Jones, CEO✅ Upcoming Events and Important Dates for 2024!✅ Case Study: One Nucleus’ Facility Management for Constructive Bio✅ Congratulations to PrecisionLife and LifeArc, winners of the Genesis BioNewsRound Award 2023✅ Introducing ON Helix 2024 on 4 July in Cambridge
OXFORD, BRISTOL, EDINBURGH, UK – 15 December 2023 – Leading computational biology company PrecisionLife®, which is driving precision medicine in complex chronic diseases, the ME/CFS charity Action for M.E., and the MRC Human Genetics Unit at the Institute of Genetics and Cancer, University of Edinburgh have been awarded a £622,000 grant by Innovate UK's Advancing Precision Medicine programme to improve diagnosis and treatment for the millions of people affected by ME/CFS and long Covid.
ME/CFS and long Covid are debilitating conditions profoundly affecting the quality of life of over two…
We are excited to reach out to you, CEBR (Council of European BioRegion), network of health clusters from which your cluster is an active member, invites you to participate in a pivotal survey aimed at advancing the interests and growth of European health sector SMEs through internationalization.
About the Survey:
CEBR is at the forefront of an alliance of bio clusters dedicated to strengthening the health sector's internationalization. This survey is a cornerstone in our collective efforts to understand the unique challenges and requirements of SMEs in this dynamic…